|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:DNMT3B-SYK (FusionGDB2 ID:HG1789TG6850) |
Fusion Gene Summary for DNMT3B-SYK |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: DNMT3B-SYK | Fusion gene ID: hg1789tg6850 | Hgene | Tgene | Gene symbol | DNMT3B | SYK | Gene ID | 1789 | 6850 |
| Gene name | DNA methyltransferase 3 beta | spleen associated tyrosine kinase | |
| Synonyms | ICF|ICF1|M.HsaIIIB | p72-Syk | |
| Cytomap | ('DNMT3B')('SYK') 20q11.21 | 9q22.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | DNA (cytosine-5)-methyltransferase 3BDNA (cytosine-5-)-methyltransferase 3 betaDNA MTase HsaIIIBDNA cytosine-5--methyltransferase 3 betaDNA methyltransferase HsaIIIB | tyrosine-protein kinase SYKspleen tyrosine kinase | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | Q9UBC3 | P43405 | |
| Ensembl transtripts involved in fusion gene | ENST00000201963, ENST00000328111, ENST00000344505, ENST00000348286, ENST00000353855, ENST00000375623, ENST00000443239, ENST00000456297, | ||
| Fusion gene scores | * DoF score | 7 X 7 X 5=245 | 9 X 9 X 6=486 |
| # samples | 8 | 9 | |
| ** MAII score | log2(8/245*10)=-1.61470984411521 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(9/486*10)=-2.43295940727611 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: DNMT3B [Title/Abstract] AND SYK [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | DNMT3B(31396615)-SYK(93657968), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | DNMT3B | GO:0000122 | negative regulation of transcription by RNA polymerase II | 17303076 |
| Tgene | SYK | GO:0006468 | protein phosphorylation | 17681949 |
| Tgene | SYK | GO:0007159 | leukocyte cell-cell adhesion | 12885943 |
| Tgene | SYK | GO:0030593 | neutrophil chemotaxis | 12885943 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Top |
Fusion Gene ORF analysis for DNMT3B-SYK |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for DNMT3B-SYK |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for DNMT3B-SYK |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:31396615/:93657968) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| DNMT3B | SYK |
| FUNCTION: Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development. DNA methylation is coordinated with methylation of histones. May preferentially methylates nucleosomal DNA within the nucleosome core region. May function as transcriptional co-repressor by associating with CBX4 and independently of DNA methylation. Seems to be involved in gene silencing (By similarity). In association with DNMT1 and via the recruitment of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9. Isoforms 4 and 5 are probably not functional due to the deletion of two conserved methyltransferase motifs. Functions as a transcriptional corepressor by associating with ZHX1. Required for DUX4 silencing in somatic cells (PubMed:27153398). {ECO:0000250, ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:17303076, ECO:0000269|PubMed:18413740, ECO:0000269|PubMed:18567530, ECO:0000269|PubMed:27153398}. | FUNCTION: Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK. Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition. Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR plays also a role in T-cell receptor signaling. Plays also a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade (By similarity). Required for the stimulation of neutrophil phagocytosis by IL15 (PubMed:15123770). Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Involved in interleukin-3/IL3-mediated signaling pathway in basophils (By similarity). Also functions downstream of receptors mediating cell adhesion. Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Plays also a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response (By similarity). {ECO:0000250|UniProtKB:P48025, ECO:0000269|PubMed:12387735, ECO:0000269|PubMed:12456653, ECO:0000269|PubMed:15123770, ECO:0000269|PubMed:15388330, ECO:0000269|PubMed:19909739, ECO:0000269|PubMed:8657103, ECO:0000269|PubMed:9535867}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for DNMT3B-SYK |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for DNMT3B-SYK |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for DNMT3B-SYK |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | DNMT3B | Q9UBC3 | DB01262 | Decitabine | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | SYK | P43405 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for DNMT3B-SYK |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | DNMT3B | C4551557 | IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 1 | 11 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | DNMT3B | C0006142 | Malignant neoplasm of breast | 2 | CTD_human |
| Hgene | DNMT3B | C0678222 | Breast Carcinoma | 2 | CTD_human |
| Hgene | DNMT3B | C1257931 | Mammary Neoplasms, Human | 2 | CTD_human |
| Hgene | DNMT3B | C1458155 | Mammary Neoplasms | 2 | CTD_human |
| Hgene | DNMT3B | C4704874 | Mammary Carcinoma, Human | 2 | CTD_human |
| Hgene | DNMT3B | C0003257 | Antibody Deficiency Syndrome | 1 | CTD_human |
| Hgene | DNMT3B | C0007097 | Carcinoma | 1 | CTD_human |
| Hgene | DNMT3B | C0021051 | Immunologic Deficiency Syndromes | 1 | CTD_human |
| Hgene | DNMT3B | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
| Hgene | DNMT3B | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Hgene | DNMT3B | C0036341 | Schizophrenia | 1 | PSYGENET |
| Hgene | DNMT3B | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| Hgene | DNMT3B | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
| Hgene | DNMT3B | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
| Hgene | DNMT3B | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
| Hgene | DNMT3B | C0205699 | Carcinomatosis | 1 | CTD_human |
| Hgene | DNMT3B | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| Hgene | DNMT3B | C0376634 | Craniofacial Abnormalities | 1 | CTD_human |
| Hgene | DNMT3B | C0525045 | Mood Disorders | 1 | PSYGENET |
| Hgene | DNMT3B | C0796113 | Nephroblastomatosis, fetal ascites, macrosomia and Wilms tumor | 1 | GENOMICS_ENGLAND |
| Hgene | DNMT3B | C1510586 | Autism Spectrum Disorders | 1 | CTD_human |
| Hgene | DNMT3B | C1656427 | Early onset schizophrenia | 1 | PSYGENET |
| Hgene | DNMT3B | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| Hgene | DNMT3B | C1834671 | FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1B | 1 | UNIPROT |
| Hgene | DNMT3B | C2931456 | Prostate cancer, familial | 1 | CTD_human |
| Hgene | DNMT3B | C4722327 | PROSTATE CANCER, HEREDITARY, 1 | 1 | CTD_human |
| Tgene | C0025202 | melanoma | 1 | CTD_human | |
| Tgene | C0025500 | Mesothelioma | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies